470 related articles for article (PubMed ID: 31471313)
21. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
22. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
Kajiura S; Hosokawa A; Nanjyo S; Nakada N; Ando T; Sugiyama T
Nihon Shokakibyo Gakkai Zasshi; 2016 Apr; 113(4):655-61. PubMed ID: 27052395
[TBL] [Abstract][Full Text] [Related]
23. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
[TBL] [Abstract][Full Text] [Related]
25. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
26. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
27. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
28. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Le Cesne A; Blay JY; Reichardt P; Joensuu H
Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.
Verschuur AC; Bajčiová V; Mascarenhas L; Khosravan R; Lin X; Ingrosso A; Janeway KA
Cancer Chemother Pharmacol; 2019 Jul; 84(1):41-50. PubMed ID: 31006038
[TBL] [Abstract][Full Text] [Related]
30. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
[TBL] [Abstract][Full Text] [Related]
32. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Nemunaitis J; Bauer S; Blay JY; Choucair K; Gelderblom H; George S; Schöffski P; Mehren MV; Zalcberg J; Achour H; Ruiz-Soto R; Heinrich MC
Future Oncol; 2020 Jan; 16(1):4251-4264. PubMed ID: 31755321
[TBL] [Abstract][Full Text] [Related]
33. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
34. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM
Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608
[TBL] [Abstract][Full Text] [Related]
35. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
[TBL] [Abstract][Full Text] [Related]
36. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
Rosenbaum E; Kelly C; D'Angelo SP; Dickson MA; Gounder M; Keohan ML; Movva S; Condy M; Adamson T; Mcfadyen CR; Antonescu CR; Hwang S; Singer S; Qin LX; Tap WD; Chi P
Oncologist; 2019 Oct; 24(10):1309-e983. PubMed ID: 31213500
[TBL] [Abstract][Full Text] [Related]
37. Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature.
Aickara DJ; McBride J; Morrison B; Romanelli P
J Cutan Pathol; 2020 Apr; 47(4):398-401. PubMed ID: 31702819
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
[TBL] [Abstract][Full Text] [Related]
40. Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Rassner M; Waldeck S; Follo M; Jilg S; Philipp U; Jolic M; Wehrle J; Jost PJ; Peschel C; Illert AL; Duyster J; Scherer F; von Bubnoff N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]